Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

An evolving role for immunotherapy in metastatic RCC

Nature Reviews Urology volume 7, pages 305–307 (2010)Cite this article

Subjects

A large study has found no improvement in overall survival using a combination chemo-immunotherapy regimen for metastatic renal cell carcinoma, compared with immunotherapy alone. While the development of targeted therapies has provided uro-oncologists with a wider variety of treatment options, immunotherapy retains an important role in the management of metastatic renal cell carcinoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Current evidence-based treatment algorithm in metastatic RCC.

References

  1. Gore, M. E. et al. Interferon α-2a versus combination therapy with interferon α-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375, 641–648 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Atzpodien, J. et al. IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130–1136 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Négrier, S. et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil. J. Clin. Oncol. 18, 4009–4015 (2000).

    Article  PubMed  Google Scholar 

  4. [No authors listed]. Interferon-α and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353, 14–17 (1999).

  5. Escudier, B. et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).

    Article  PubMed  Google Scholar 

  6. Escudier, B. et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280–1289 (2009).

    Article  CAS  PubMed  Google Scholar 

  7. Di Lorenzo, G., Autorino, R. & Sternberg, C. N. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur. Urol. 56, 959–971 (2009).

    Article  CAS  PubMed  Google Scholar 

  8. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Atkins, M. et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin. Cancer Res. 11, 3714–3721 (2005).

    Article  CAS  PubMed  Google Scholar 

  10. Atkins, M. B., Choueiri, T. K., Cho, D., Regan, M. & Signoretti, S. Treatment selection for patients with metastatic renal cell carcinoma. Cancer 115 (10 Suppl.), 2327–2333 (2009).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Clinic, Second University of Naples, Piazza Miraglia 2, 80138, Naples, Italy

    Riccardo Autorino

  2. Department of Oncology, Federico II University, Via Pansini 5, 80100, Naples, Italy

    Giuseppe Di Lorenzo

Authors
  1. Riccardo Autorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Di Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Riccardo Autorino.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Autorino, R., Di Lorenzo, G. An evolving role for immunotherapy in metastatic RCC. Nat Rev Urol 7, 305–307 (2010). https://doi.org/10.1038/nrurol.2010.64

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.64

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing